Rezvilutamide for High-Risk Prostate Cancer After Surgery

NCT07444983 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer (Adenocarcinoma)

Interventions

DRUG: Rezvilutamide and Leuprorelin

Sponsor

Fujian Medical University Union Hospital